Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL

Bone Marrow Transplantation volume 49, pages 1259–1265 (2014)Cite this article

Subjects

Abstract

Although most children with ALL can be cured by chemotherapy approaches, allogeneic hematopoietic cell transplant (HCT) therapy offers a better chance of cure to selected high-risk patients in first remission and most children who relapse. Although transplant-related mortality has decreased significantly in the past decade, relapse remains high after HCT for ALL; developing strategies to decrease relapse and improve survival are vital. Recent studies have shown that relapse risk can be accurately defined using measurements of minimal residual disease (MRD) both pre- and post-HCT and by knowing whether patients get GVHD in the first 2 months after transplant. With these risk definitions in hand, investigators are now applying novel agents and immunotherapeutic methods in attempt to lower MRD before transplant and modulate the GVL effect after transplant. With powerful new immunological approaches coming on line, the transplant process itself will likely expand to include pre and/or post-HCT interventions aimed at reducing relapse.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012; 30: 1663–1669.

    Article  PubMed  PubMed Central  Google Scholar 

  2. MacMillan ML, Davies SM, Nelson GO, Chitphakdithai P, Confer DL, King RJ et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14 (9 Suppl): 16–22.

    Article  PubMed  Google Scholar 

  3. Hahn T, McCarthy PL Jr, Hassebroek A, Bredeson C, Gajewski JL, Hale GA et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013; 31: 2437–2449.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011; 118: 223–230.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pulsipher MA, Bader P, Klingebiel T, Cooper LJ . Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant 2008; 15 (1 Suppl): 62–71.

    Google Scholar 

  6. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  7. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27: 5175–5181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110: 1112–1115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45: 242–252.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012; 366: 1371–1381.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Moricke A et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118: 2077–2084.

    Article  CAS  PubMed  Google Scholar 

  12. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008; 111: 5477–5485.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730–2741.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Schrauder A, von Stackelberg A, Schrappe M, Cornish J, Peters C . Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplant 2008; 41 (Suppl 2): S71–S74.

    Article  PubMed  Google Scholar 

  15. Dreyer Z, Dinndorf PA, Camitta B, Sather H, La MK, Devidas M et al. Prospective analysis of the role of hematopoietic stem cell transoplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children’s Oncology Group. J Clin Oncol 2010; 29: 214–222.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010; 116: 2644–2650.

    Article  CAS  PubMed  Google Scholar 

  17. Heerema NA, Carroll AJ, Devidas M, Loh ML, Borowitz MJ, Gastier-Foster JM et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. J Clin Oncol 2013; 31: 3397–3402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Moorman AV, Robinson H, Schwab C, Richards SM, Hancock J, Mitchell CD et al. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol 2013; 31: 3389–3396.

    Article  PubMed  Google Scholar 

  19. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470–480.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Loh ML, Zhang J, Harvey RC, Roberts K, Payne-Turner D, Kang H et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children’s Oncology Group TARGET Project. Blood 2013; 121: 485–488.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grumayer R et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 2013; 31: 2736–2742.

    Article  PubMed  Google Scholar 

  22. Saarinen-Pihkala UM, Heilmann C, Winiarski J, Glomstein A, Abrahamsson J, Arvidson J et al. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol 2006; 24: 5750–5762.

    Article  PubMed  Google Scholar 

  23. Reid GS, Terrett L, Alessandri AJ, Grubb S, Stork L, Seibel N et al. Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells. Leuk Res 2003; 27: 1135–1142.

    Article  CAS  PubMed  Google Scholar 

  24. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27: 377–384.

    Article  PubMed  Google Scholar 

  25. Elorza I, Palacio C, Dapena JL, Gallur L, Sanchez de Toledo J, Diaz de Heredia C . Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica 2010; 95: 936–941.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012; 120: 468–472.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Foster JH, Hawkins DS, Loken MR, Wells DA, Thomson B . Minimal residual disease detected prior to hematopoietic cell transplantation. Pediatr Blood Cancer 2011; 57: 163–165.

    Article  PubMed  Google Scholar 

  28. Pulsipher M, Langholz B, Wall D, Schultz K, Bunin N, Carroll WL et al. Addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase III COG/PBMTC trial. Blood 2014; 123: 2017–2025.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511–516.

    Article  PubMed  Google Scholar 

  30. Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant 2008; 42: 201–205.

    Article  CAS  PubMed  Google Scholar 

  31. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730–3738.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Cornelissen JJ, Carston M, Kollman C, King R, Dekker AW, Lowenberg B et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572–1577.

    Article  CAS  PubMed  Google Scholar 

  33. Passweg JR, Tiberghien P, Cahn JY, Vowels MR, Camitta BM, Gale RP et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21: 153–158.

    Article  CAS  PubMed  Google Scholar 

  34. Lee S, Cho BS, Kim SY, Choi SM, Lee DG, Eom KS et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 1083–1094.

    Article  PubMed  Google Scholar 

  35. Nordlander A, Mattsson J, Ringden O, Leblanc K, Gustafsson B, Ljungman P et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2004; 10: 195–203.

    Article  PubMed  Google Scholar 

  36. Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Bregante S et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 1998; 83: 896–903.

    CAS  PubMed  Google Scholar 

  37. Locatelli F, Zecca M, Messina C, Rondelli R, Lanino E, Sacchi N et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002; 16: 2228–2237.

    Article  CAS  PubMed  Google Scholar 

  38. Gustafsson Jernberg A, Remberger M, Ringden O, Winiarski J . Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. Bone Marrow Transplant 2003; 31: 175–181.

    Article  CAS  PubMed  Google Scholar 

  39. Dini G, Zecca M, Balduzzi A, Messina C, Masetti R, Fagioli F et al. No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood 2011; 118: 6683–6690.

    Article  CAS  PubMed  Google Scholar 

  40. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ et al. Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma. J Clin Oncol 2008; 26: 3971–3978.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696–1705.

    Article  PubMed  Google Scholar 

  42. Pasquini MC, Wang Z . Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2012. Available at: http://www.cibmtr.org

  43. Bishop MR, Alyea EP 3rd, Cairo MS, Falkenburg JH, June CH, Kroger N et al. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010; 16: 563–564.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2005; 11: 823–861.

    Article  PubMed  Google Scholar 

  45. Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant 2012; 18: 505–522.

    Article  CAS  PubMed  Google Scholar 

  46. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S . Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003; 32: 543–548.

    Article  CAS  PubMed  Google Scholar 

  47. Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340–347.

    Article  CAS  PubMed  Google Scholar 

  48. Wayne AS, Radich JP . Pretransplant MRD the light is yellow, not red. Blood 2012; 120: 244–246.

    Article  CAS  PubMed  Google Scholar 

  49. Zhang MJ, Davies SM, Camitta BM, Logan B, Tiedemann K, Eapen M et al. Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012; 18: 1204–1210.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringden O et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872–4880.

    Article  PubMed  Google Scholar 

  51. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333–339.

    CAS  PubMed  Google Scholar 

  52. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174: 6540–6545.

    Article  CAS  PubMed  Google Scholar 

  53. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172 644–650.

    Article  CAS  PubMed  Google Scholar 

  54. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572–1579.

    CAS  PubMed  Google Scholar 

  55. Napper AD, Watson VG . Targeted drug discovery for pediatric leukemia. Front Oncol 2013; 3: 170.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Shah NN, Dave H, Wayne AS . Immunotherapy for pediatric leukemia. Front Oncol 2013; 3: 166.

    PubMed  PubMed Central  Google Scholar 

  57. Wayne AS, Giralt S, Kroger N, Bishop MR . Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Introduction. Biol Blood Marrow Transplant 2013; 19: 1534–1536.

    Article  PubMed  Google Scholar 

  58. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509–1518.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported in part by N01 HC-45220/HHSN268200425220C, U10 CA098543 and R01CA1116660. PBMTC activities were supported by 2U01HL069254 and the St Baldrick’s Foundation.

Author information

Authors and Affiliations

  1. Division of Hematology and Hematological Malignancies, Primary Children’s Hospital, University of Utah School of Medicine/Huntsman Cancer Institute, Salt Lake City, UT, USA,

    M A Pulsipher

  2. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, The Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    A S Wayne

  3. Department of Pediatrics, University of BC, BC Children's Hospital, Vancouver, British Columbia, Canada

    K R Schultz

Authors
  1. M A Pulsipher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A S Wayne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K R Schultz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Pulsipher.

Ethics declarations

Competing interests

ASW is a co-inventor on patents assigned to the United States Government, as represented by the Secretary, Department of Health and Human Services (National Institutes of Health), for some of the investigational products reviewed in this paper. ASW also receives financial support through a Research Service Agreement between Children’s Hospital Los Angeles and MedImmune, LLC. KRS is Vice-Chair of a protocol run through the Therapeutic Advances in Acute Leukemia Consortium that is sponsored by SBI Biotech. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pulsipher, M., Wayne, A. & Schultz, K. New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL. Bone Marrow Transplant 49, 1259–1265 (2014). https://doi.org/10.1038/bmt.2014.114

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.114

This article is cited by

Search

Advanced search

Quick links